Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological and Regenerative Medicine Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ID2 (Inhibitor of DNA Binding 2) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human ID2 Protein (Full Length / HLH Domain) High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spectrometry. Ideal for PPI screening. |
View ID2 Products |
| Gene Delivery | ID2 Promise-ORF / Lentivirus Particles Full-length ORF for stable cell line generation and functional transcriptional reporter assays. |
View ID2 Products |
| Benchmark Ab | Recombinant Anti-ID2 Antibody High-affinity sequence-verified positive control for Western Blot, IP, and ChIP validation. |
View ID2 Products |
| Validator | ID2 siRNA Set Target-specific gene knockdown validation to confirm phenotypic specificity. |
View ID2 Products |
| Related Target A | TCF3 (E2A) Primary bHLH transcription factor partner. Restoring TCF3 activity by blocking ID2 is a key therapeutic mechanism. |
View TCF3 Products |
| Related Target B | MYCN (N-Myc) Upstream oncogenic driver of ID2 expression in neuroblastoma and small cell lung cancer. |
View MYCN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein Aggregation & Instability | HEK293 and E. coli optimized expression systems preserving monomeric HLH conformation. |
| PPI Screening (ID2-bHLH Interaction) | Biotinylated and Tagged ID2 recombinant proteins optimized for SPR, MST, and AlphaLISA assays. |
| Lack of Controls | Sequence-derived recombinant benchmark antibodies for robust assay baselines. |
| Off-Target Effects | Homology screening panels (ID1, ID3, ID4) for high-specificity profiling. |
Live ID2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of ID2 (Inhibitor of DNA Binding 2) is gaining significant momentum as oncology R&D shifts toward undruggable transcription factors. ID2 acts as a dominant-negative regulator of basic helix-loop-helix (bHLH) transcription factors, promoting cell cycle progression, stemness, and immune evasion in glioblastoma, neuroblastoma, and triple-negative breast cancer (TNBC).
While historically considered "undruggable" due to its lack of a deep pocket for small-molecule binding, modern modalities are breaking these barriers. Current clinical and preclinical strategies are heavily focused on Targeted Protein Degradation (PROTACs/Molecular Glues), RNA therapeutics (siRNA/ASOs), and small-molecule peptide mimetics designed to disrupt the critical ID2-bHLH heterodimerization interface.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Arvinas, C4 Therapeutics | Glioblastoma, Solid Tumors | Ternary Complex Formation Assay (Need High-Purity Tagged ID2 & E3 Ligase Proteins) |
| RNAi / ASO | Alnylam, Ionis Pharmaceuticals | Neuroblastoma, Glioma | Target Knockdown Validation (Need High-Efficiency siRNA & Lentiviral Reporters) |
| Small Mol (PPI Inhibitor) | Academic Consortia, Biotech Startups | Hematological Malignancies, SCLC | Biophysical Binding Assays (Need Stable, Non-aggregating ID2 HLH Domain Proteins) |